| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 5.09▼ | 5.07▼ | 5.04▼ | 4.87▲ | 4.85▲ |
| MA10 | 5.10▼ | 5.02▼ | 4.97▲ | 4.87▲ | 4.94▲ |
| MA20 | 5.06▼ | 4.95▲ | 4.87▲ | 4.83▲ | 3.92▲ |
| MA50 | 4.94▲ | 4.83▲ | 4.85▲ | 5.04▲ | N/A |
| MA100 | 4.84▲ | 4.86▲ | 4.80▲ | 3.84▲ | N/A |
| MA200 | 4.86▲ | 4.80▲ | 5.41▼ | N/A | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.009▼ | 0.010▲ | 0.026▲ | 0.000▼ | 0.297▲ |
| RSI | 48.751▼ | 56.398▲ | 56.812▲ | 52.036▲ | 48.408▼ |
| STOCH | 52.156 | 81.536▲ | 80.952▲ | 35.708 | 31.443 |
| WILL %R | -100.000▼ | -35.714 | -35.714 | -36.190 | -56.006 |
| CCI | -82.927 | 70.286 | 92.153 | 123.427▲ | 27.647 |
|
Wednesday, November 12, 2025 05:13 AM
Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose ...
|
|
Thursday, October 30, 2025 05:11 AM
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today ...
|
|
Monday, October 06, 2025 07:32 AM
) has been revised to $15.64 / share. This is an increase of 33.33% from the prior estimate of $11.73 dated September 10, 2025. The price target is an average of many targets provided by analysts. The ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/11/25 | 4.8444 | 5.24 | 4.8444 | 5.07 | 97,888 |
| 10/11/25 | 4.75 | 5.07 | 4.5019 | 4.80 | 122,217 |
| 07/11/25 | 4.80 | 4.825 | 4.51 | 4.75 | 292,223 |
| 06/11/25 | 4.925 | 5.10 | 4.54 | 4.73 | 203,671 |
| 05/11/25 | 4.73 | 5.03 | 4.70 | 5.00 | 118,679 |
| 04/11/25 | 4.82 | 4.99 | 4.67 | 4.71 | 35,807 |
| 03/11/25 | 5.10 | 5.45 | 4.785 | 4.99 | 108,451 |
| 31/10/25 | 4.76 | 5.12 | 4.71 | 5.03 | 49,315 |
| 30/10/25 | 4.84 | 4.905 | 4.70 | 4.74 | 23,578 |
| 29/10/25 | 4.98 | 5.15 | 4.71 | 4.87 | 42,418 |
|
|
||||
|
|
||||
|
|